MedWatch

Neurosearch: We are keeping our options open

Increased demands from the FDA means that Neurosearch will need to be flexible in its negotiations with a possible partner. CEO admits that it will have consequences.

Foto: Jyllands-Posten

Anything could happen; that brief statement sums up the answers given by Patrick Dahlen, CEO of Neurosearch, after the company last week had to concede that it will be more difficult than initially thought to gain American approval for Huntexil, the company’s Huntington’s disease drug.

In order to finance the phase III studies of Huntexil, Neurosearch will need a partner, and new rules could determine exactly which role the biotech company will play in a future partnership. Because of new requirements the company has had to give up on the European rights for Huntexil.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier